APTO - Why Aptose Biosciences Stock Sank Today
Shares of Aptose Biosciences (NASDAQ: APTO) were sinking 11.9% as of 3:13 p.m. EDT on Monday. The decline came after the company presented preliminary clinical data from an early-stage clinical study evaluating CG-806 in treating relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), or non-Hodgkin lymphoma (NHL). The presentation was included in the American Association for Cancer Research (AACR) Virtual Annual Meeting.
Aptose's results included only limited information. The company said that the study has completed three dose levels with no drug-related severe adverse events reported so far.
Image source: Getty Images.